A Study to Evaluate the Effects of MK-4305 in Patients With Chronic Obstructive Pulmonary Disease.
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck & Co
- 31 Jul 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
- 31 Jul 2012 Actual patient number changed from 24 to 25 and actual initiation date changed from Apr 2011 to Mar 2011 as reported by ClinicalTrials.gov.
- 12 Mar 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.